Basiratnia Mitra, Yavarian Majid, Torabinezhad Simin, Erjaee Asma
Shiraz Nephrology Urology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Kidney Dis. 2013 Sep;7(5):357-62.
Mutations in podocin (NPHS2) gene have the key role in the pathogenesis of steroid-resistant nephrotic syndrome (SRNS) in children, but data is scarce regarding their prevalence and natural course among different all ethnic groups. This study was aimed to demonstrate the spectrum of NPHS2 mutations in children with SRNS and to compare the clinical course of disease in patients with and without mutation.
All 8 exons of NPHS2 were sequenced in 99 children, including 49 with SRNS and 50 with steroid-sensitive nephrotic syndrome (control group) by DNA sequencing.
The prevalence rates of NPHS2 gene mutation among children with SRNS and SSNS were 31% and 4%, respectively. The prevalence rates of mutation among familial and sporadic forms were 57% and 26%, respectively. Thirty-three percent of the children experienced recurrence of primary disease after kidney transplantation, none of whom had a mutation. The clinical response to treatment was poorer in children with mutation in comparison with patients without mutation (12% versus 32%, respectively; odds ratio, 3.29, 95% confidence interval, 0.40 to 25.64). Patients with and without mutation could not be differentiated by demographic and histological features, glomerular filtration rate at onset, hypertension, progression to end-stage renal disease, and proteinuria.
Mutations of NPHS2 gene are frequent among Iranian children with SRNS. Regarding similar clinical features in patients with and without mutation and poor response to pharmacotherapy in patients with mutation, a molecular approach might be necessary for different treatment plans and prediction of prognosis.
足突蛋白(NPHS2)基因突变在儿童激素抵抗型肾病综合征(SRNS)的发病机制中起关键作用,但关于其在不同种族群体中的患病率和自然病程的数据却很稀少。本研究旨在阐明SRNS患儿中NPHS2基因突变的情况,并比较有突变和无突变患者的疾病临床过程。
通过DNA测序对99名儿童的NPHS2基因的所有8个外显子进行测序,其中包括49例SRNS患儿和50例激素敏感型肾病综合征患儿(对照组)。
SRNS患儿和SSNS患儿中NPHS2基因突变的患病率分别为31%和4%。家族性和散发性形式中突变的患病率分别为57%和26%。33%的儿童在肾移植后出现原发性疾病复发,其中无一例有突变。与无突变患者相比,有突变的儿童对治疗的临床反应较差(分别为12%和32%;优势比为3.29,95%置信区间为0.40至25.64)。有突变和无突变的患者在人口统计学和组织学特征、发病时的肾小球滤过率、高血压、进展至终末期肾病以及蛋白尿方面无法区分。
NPHS2基因突变在伊朗SRNS患儿中很常见。鉴于有突变和无突变患者具有相似的临床特征,且有突变患者对药物治疗反应不佳,对于不同的治疗方案和预后预测,分子方法可能是必要的。